Genetic markers in oligodendroglial tumours

被引:9
|
作者
Velnar, Tomaz [1 ,2 ]
Smrdel, Uros [2 ]
Popovic, Mara [3 ]
Bunc, Gorazd [1 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurosurg, Maribor 2000, Slovenia
[2] Inst Oncol Ljubljana, Ljubljana, Slovenia
[3] Univ Ljubljana Fac Med, Dept Pathol, Ljubljana, Slovenia
关键词
oligodendroglioma; genetic markers; chemotherapy; prognosis; ANAPLASTIC OLIGODENDROGLIOMA; BRAIN-TUMORS; PHASE-II; ADJUVANT TREATMENT; PROGNOSTIC-FACTORS; MOLECULAR-BIOLOGY; GLIOMA PATIENTS; 19Q DELETIONS; TEMOZOLOMIDE; CHEMOTHERAPY;
D O I
10.2478/v10019-010-0007-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5-20% of all gliomas. Conclusions. Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [1] Genetic abnormalities in oligodendroglial and ependymal tumours
    Goussia, AC
    Kyritsis, AP
    Mitlianga, P
    Bruner, JM
    JOURNAL OF NEUROLOGY, 2001, 248 (12) : 1030 - 1035
  • [2] Genetic abnormalities in oligodendroglial and ependymal tumours
    Ann C. Goussia
    Athanassios P. Kyritsis
    Paraskevi Mitlianga
    Janet M. Bruner
    Journal of Neurology, 2001, 248 : 1030 - 1035
  • [3] Chemotherapy of anaplastic oligodendroglial tumours
    Soffietti, R
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (02) : 295 - 306
  • [4] Familial occurrence of oligodendroglial tumours
    Flannery, T.
    Cawley, D.
    Zulfiger, A.
    Alderazi, Y.
    Heffernan, J.
    Brett, F.
    Farrell, M.
    O'Brien, D. F.
    BRITISH JOURNAL OF NEUROSURGERY, 2008, 22 (03) : 436 - 438
  • [5] Salvage radiotherapy in oligodendroglial tumours
    Costanza, A
    Laguzzi, E
    Nobile, M
    Rudà, R
    Beltramo, G
    Mantovani, C
    Mutani, R
    Soffietti, R
    JOURNAL OF NEUROLOGY, 2004, 251 : 147 - 147
  • [6] Methylation Profile in Oligodendroglial Tumours
    Mur, P.
    Perez-Magan, E.
    Mollejo, M.
    Fiano, C.
    Garcia, J. F.
    Rey, J. A.
    Melendez, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S136 - S137
  • [7] Genetic aberrations in oligodendroglial tumours: An analysis using comparative genomic hybridization (CGH)
    Kros, JM
    Van Run, PRWA
    Alers, JC
    Beverloo, HB
    Van den Bent, MJ
    Avezaat, CJJ
    Van Dekken, H
    JOURNAL OF PATHOLOGY, 1999, 188 (03): : 282 - 288
  • [8] Longitudinal assessment of genetic and epigenetic markers in progressive oligodendroglial tumors (OT)
    Lavon, I.
    Zelikovitsh, B.
    Zrihan, Daniel
    Fellig, Y.
    Soffer, D.
    Siegall, T.
    NEURO-ONCOLOGY, 2006, 8 (04) : 460 - 460
  • [9] The relationship between genetic and nongenetic features in oligodendroglial tumours: can morphology replace molecular genetic typing?
    Scheie, D.
    Cvancarova, M.
    Mork, S.
    Skullerud, K.
    Andresen, P. A.
    Benestad, I.
    Helseth, E.
    Meling, T.
    Beiske, K.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2007, 33 (02) : 260 - 260
  • [10] Pleiotrophin expression in astrocytic and oligodendroglial tumours
    Neder, Luciano
    Peria, Fernanda M.
    Rosemberg, Sergio
    Oba-Shinjo, Sueli M.
    Malheiros, Suzana M.
    Marie, Suely K.
    Okamoto, Oswaldo K.
    Colli, Benedicto O.
    Zago, Marco A.
    Carlotti, Carlos G., Jr.
    BRAIN PATHOLOGY, 2006, 16 : S35 - S35